These individuals and their organisations will benefit from two new types of NPC 'On the Horizon' bulletin to keep them up-to-date with emerging key treatments. Future Medicines will give details of some of the most significant new medicines around six months before they are launched and Rapid Review will provide relevant additional information on these medicines, within two months of their launch.
The new scheme will involve more effective and timely communication and cooperation between the NPC and the relevant pharmaceutical companies to ensure information provided to NHS organisations is as timely, comprehensive and useful as possible. The new style bulletins will continue to be effectively co-ordinated with the NICE appraisals process.
Martin Anderson, Director of Commercial Affairs at the ABPI said: "By further improving the provision, to NHS organisations, of timely and useful high-quality information about new medicines, we hope it will support and encourage the appropriate uptake of new, innovative medicines".
"Patients will stand to benefit if the NHS is well informed, in advance, of the latest key developments in medication as they emerge".
Clive Jackson, Chief Executive of the NPC said: "We welcome the constructive discussions undertaken with the ABPI and the opportunities these have presented for further improving effective professional links with the pharmaceutical industry."
"By building on existing working relationships and improving communication systems, the NPC and its partners expect to be able to provide more comprehensive and timely advance information to relevant decision-makers, working within the NHS in England. This should help them to plan for the appropriate introduction of key new medicines, to the benefit of patient care, as soon as possible".
For further information, please contact: ABPI Press Office 020 7747 1410